Health
AstraZeneca’s Farxiga prolongs survival in chronic kidney disease trial – Clinical Trials Arena
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease…
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD).
The trial data showed that Farxiga helped reduce the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death.
Farxiga is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used for treating patients with insufficiently controlled type-2 diabetes (T2D).
The international, multi-centre, randomised and…
-
General16 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News23 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
Noosa News16 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General22 hours agoCrowe toasts talkback titan for platforming ‘voiceless’